Roche【0QQ6】銘柄情報

Roche Holding AG (0QQ6) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

229.20

( - )

買値

229.20

売値

229.20

出来高

167

0.00 日の範囲 0.00

229.20 52 週間の範囲 229.20

時価総額

182.356B

前日終値

229.20

始値

時刻

343.4

(O)

最終取引時間

23:18:28

財務取引量

VWAP

平均取引量 (3 か月)

CHF 1,010,744

発行済株式数

795,617,637

配当利回り

9.8 (3.11%)

PER

19.86

1 株当たり利益 (EPS)

16.04

歳入

63.36B

純利益

12.88B

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases... Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland. 詳細を表示

セクター

業界

ウェブサイト

www.roche.com

本社

Basel, Switzerland

設立

1896

Roche Holding AG is listed in the sector of the ロンドン証券取引所 with ticker 0QQ6. The last closing price for Roche was CHF229.20. Over the last year, Roche shares have traded in a share price range of CHF 229.20 to CHF 229.20.

Roche currently has 795,617,637 shares in issue. The market capitalisation of Roche is CHF182.36 billion. Roche has a price to earnings ratio (PE ratio) of 19.86.

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform AXELIOS 1 delivers a unique combination of accuracy...

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large...

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer The new VENTANA PTEN...

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer Filing acceptance is based on the phase III Alliance...

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg...

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive...

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions Late-breaking Phase II...

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management Roche introduces the...

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer New...

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)

Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) Elecsys® pTau217...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	229.2	229.2	229.2	6575	229.2	DE
52	229.2	229.2	229.2	5943	229.2	DE
156	229.2	229.2	229.2	5285	229.2	DE
260	229.2	229.2	229.2	5718	229.2	DE